How is telogen effluvium measured?
Telogen effluvium is a form of diffuse, non-scarring hair loss characterised by the premature shedding of telogen-phase hairs. This page outlines the instruments and endpoints used to measure it in research settings, inc
How is telogen effluvium measured?
Telogen effluvium is a form of diffuse, non-scarring hair loss in which an increased proportion of scalp hairs enter the telogen (resting) phase and are shed prematurely. It is also referred to in the literature as telogen hair loss or telogen defluvium. In research settings, it is not a single laboratory value but a composite of clinical assessment, quantitative hair measurements, and participant-reported outcomes. The registered study described in the evidence block measures telogen effluvium associated with GLP-1 receptor agonist use using three instrument families: clinical assessments, hair measurements via trichogram, and participant questionnaires, over a 120-day supplement-use period [1].
The work centres on the glucagon-like peptide 1 receptor (GLP-1R) and, in some agents, the dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor pathway, because the hair-loss signal being measured arises in patients receiving GLP-1 receptor agonists (GLP-1RAs) [2].
Research Studies
Trichogram and telogen effluvium in GLP-1 receptor agonist users
A trichogram is a hair-sampling method used to quantify the proportion of hairs in each phase of the hair cycle. In the registered study of GLP-1-associated telogen effluvium, the trichogram is listed as one of the hair measurements used to evaluate hair loss over 120 days of supplement use [1]. The trichogram provides a phase-distribution count rather than a clinical impression alone, which is why it is grouped with clinical assessments and questionnaires in that protocol [1].
Hair density and hair growth measurement in GLP-1-associated telogen effluvium
Hair density and hair growth are named endpoints in the same registered study. Researchers evaluate hair loss, hair density, and hair growth through clinical assessments, hair measurements (trichogram), and participant questionnaires [1]. These are distinct from the trichogram phase count: density and growth describe the amount and output of hair, while the trichogram describes the phase distribution of sampled hairs [1].
Participant questionnaires in telogen effluvium research
Participant questionnaires are the third measurement family in the registered protocol. They are used alongside clinical assessments and trichogram measurements to evaluate hair loss in women with GLP-1-associated telogen effluvium [1]. Questionnaire data are subjective by design and are therefore reported as one component of a multi-instrument assessment rather than as a standalone measure [1].
Clinical assessment as a telogen effluvium endpoint
Clinical assessment is the first-listed evaluation method in the registered study. It is used together with hair measurements and questionnaires to evaluate hair loss, hair density, and hair growth in participants using the supplement for 120 days [1]. The protocol does not rely on any single instrument; the three families are combined [1].
GLP-1 receptor agonist-associated hair loss: population and context
The population in which the hair-loss signal has been observed is patients receiving GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists. These agents are used to improve glycaemic control in patients with type 2 diabetes mellitus, and some are also used to help with weight loss [2]. Safety signals concerning a possible link between GLP-1RA therapies and hair loss have been emerging in the USA, and with increasing prescription volumes in Europe, an increase in GLP-1RA-associated hair loss cases is expected there over the coming years [2].
Measurement instruments compared
| Instrument | What it measures | Study context |
|---|---|---|
| Clinical assessment | Hair loss, hair density, hair growth | Used in the 120-day registered study of GLP-1-associated telogen effluvium [1] |
| Trichogram | Hair measurements, including phase distribution of sampled hairs | Used in the same registered study [1] |
| Participant questionnaire | Participant-reported hair loss outcomes | Used in the same registered study [1] |
Study design and duration in telogen effluvium measurement
The registered study is a single-centre, open-label clinical study. Participants use the dietary supplement for 120 days, and the three measurement families are applied to evaluate hair loss, hair density, and hair growth [1]. The open-label design means participants and investigators are aware of the supplement assignment; the evidence block does not describe a comparator arm [1].
Pharmacological context for GLP-1RA hair-loss measurement
The commentary source considers the pharmacological context and market expansion for GLP-1RAs and examines the hair-loss signal in that context [2]. It does not provide a measurement protocol; it frames why measurement in this population is of interest as prescriptions increase in Europe [2].
What the evidence does not establish
The evidence block does not provide a validated cut-off, a normal reference range, or a minimum detectable change for any of the three instruments. It does not report results from the registered study, and it does not establish that any supplement alters trichogram values, hair density, or questionnaire scores [1]. The commentary source describes a safety signal and expected case growth; it does not quantify the risk or establish causation [2]. No animal-only or in vitro measurement data are provided in the evidence block.
If you are reading this for personal health reasons
The materials described on this page are sold for laboratory research use only. We do not provide dosing, medical guidance, or personal health advice. Anyone considering a compound for themselves should speak to a licensed clinician.